Market Place
Sourcing Support
scPharma Inc. Reports Q3 2024 Financial Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Q3 2024 Financials on Nov 13
06 Nov 2024 //
GLOBENEWSWIRE
scPharmaceuticals to Host Key Opinion Leader Webinar on Oct 22, 2024
15 Oct 2024 //
GLOBENEWSWIRE
scPharmaceuticals To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
scPharmaceuticals Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
12 Aug 2024 //
GLOBENEWSWIRE
scPharmaceuticals Announces Public Offering Of Stock And Warrants
12 Aug 2024 //
GLOBENEWSWIRE
scPharmaceuticals Reports Positive Results For SCP-111 Autoinjector
12 Aug 2024 //
GLOBENEWSWIRE
FDA Approves FUROSCIX Indication Expansion In Heart Failure
12 Aug 2024 //
GLOBENEWSWIRE
scPharmaceuticals Secures $125M Non-Dilutive Financing
12 Aug 2024 //
GLOBENEWSWIRE
scPharmaceuticals` sNDA For FUROSCIX CKD Indication Accepted
25 Jul 2024 //
GLOBENEWSWIRE
scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
scPharmaceuticals Reports Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
scPharmaceuticals At HC Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
scPharmaceuticals Q1 2024 Results on May 14
06 May 2024 //
GLOBENEWSWIRE
scPharmaceuticals Enrolls First FUROSCIX Auto-Injector Study Patient
24 Apr 2024 //
GLOBENEWSWIRE
scPharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Fourth Quarter & Full-Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
28 Feb 2024 //
GLOBENEWSWIRE
scPharmaceuticals Announces Q4 and Full-Year 2023 Net FUROSCIX® Revenue
04 Jan 2024 //
GLOBENEWSWIRE
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
31 Oct 2023 //
GLOBENEWSWIRE
scPharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2023 //
GLOBENEWSWIRE
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings
19 Sep 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
scPharmaceuticals Announces Feedback from FDA on Heart Failure Class IV Indication Expansion
01 Aug 2023 //
GLOBENEWSWIRE
scPharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
19 Jul 2023 //
GLOBENEWSWIRE
scPharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
23 Jun 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
scPharmaceuticals Inc. Reports 1Q 2023FYR &Provides Business Update
10 May 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Announce First Quarter 2023 FYR on Wednesday, May 10, 2023
02 May 2023 //
GLOBENEWSWIRE
scPharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Fourth Quarter & Full-Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
23 Feb 2023 //
GLOBENEWSWIRE
scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX
21 Feb 2023 //
GLOBENEWSWIRE
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
06 Feb 2023 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in SVB Securities Global Biopharma Conference
31 Jan 2023 //
GLOBENEWSWIRE
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
30 Jan 2023 //
GLOBENEWSWIRE
scPharmaceuticals Announces Appointment of Rachael Nokes as CFO
19 Dec 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in Annual LifeSci Partners Corp Access Event
14 Dec 2022 //
GLOBENEWSWIRE
scPharmaceuticals Announces Pricing of $50 Million Public Offering
22 Nov 2022 //
GLOBENEWSWIRE
ScPharmaceuticals raises $50M for launch of on-body infusor
22 Nov 2022 //
FIERCEPHARMA
scPharmaceuticals Announces Proposed Underwritten Public Offering of Stock
21 Nov 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Announce Third Quarter 2022 Financial Results
26 Oct 2022 //
GLOBENEWSWIRE
FDA signs off on scPharmaceutical’s on-body infusor for HF
11 Oct 2022 //
FIERCEPHARMA
scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide)
10 Oct 2022 //
GLOBENEWSWIRE
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
10 Oct 2022 //
GLOBENEWSWIRE
scPharmaceuticals Announces Data Presentations at the Heart Failure Society
30 Sep 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global
01 Sep 2022 //
GLOBENEWSWIRE
scPharmaceuticals Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
scPharmaceuticals Announces Positive Results from AT HOME-HF PII Pilot Study
12 Jul 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Host FUROSCIX 80mg/10mL for Subcutaneous Administration
30 Jun 2022 //
GLOBENEWSWIRE
scPharmaceuticals Announces Abstracts Accepted for Presentation at the AAHFN
07 Jun 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Present at the Jefferies Healthcare Conference
24 May 2022 //
GLOBENEWSWIRE
scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX New Drug Application
16 May 2022 //
GLOBENEWSWIRE
scPharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
